(Q34265391)

English

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

adaptive radiation therapy

0 references

head and neck carcinoma

1 reference

based on heuristic

inferred from title

object named as

Elo Andersen

6

0 references

Jørgen Johansen

object named as

Jørgen Johansen

10

0 references

object named as

Lars Bastholt

8

0 references

object named as

Cai Grau

5

0 references

object named as

Lena Specht

3

0 references

author name string

Jens Overgaard

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hanne Sand Hansen

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Marie Overgaard

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jens Bentzen

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Olfred Hansen

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lisbeth Andersen

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jan F Evensen

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

362

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

9388

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

933-940

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy for cancer of the head and neck: altered fractionation regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of accelerated hyperfractionation for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

ARCON: a novel biology-based approach in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting epidermal growth factor receptor--are we missing the mark?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management and outcome differences in supraglottic cancer between Ontario, Canada, and the Surveillance, Epidemiology, and End Results areas of the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914361-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(03)14361-9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34265391&oldid=1587531447"